Stemline Therapeutics

NAS:STML

Biotechnology

Market Cap

—

SMALL cap

Share Price↑↓←

(—)

YTD Return ↑↓←

—

since start of 2022

P/E Ratio

—

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data & Privacy Protection
Consumer Health, Wellness & Safety
Employee Ownership, Satisfaction, Benefits & Pay
Workplace Health and Safety
Integrity of Corporate Governance
Ethical Practices
Usage of Conflict Materials
Forced Labor
Diversity of Corporate Leadership

About

BiotechnologyFounded 2003

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. It develops a discovery platform called StemScreen, which identifies novel compounds that target and kill cancer stem cells. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Headquarters

750 Lexington Avenue

11th floor

New York, NY 10022

1.646.502.2310

Executives

Name	Title	Gender
Ivan Bergstein, MD	Chairman, President & Chief Executive Officer	Male
David G. Gionco, MBA, CPA	Principal Financial Officer	Male
Kenneth Hoberman	Chief Operating Officer & Secretary	Male

Mindful Investing Summary

Carbon Footprint
—N/A
Stemline Therapeutics among its competitors for its carbon footprint. A company’s performance in this category is based on its success in implementing energy efficiency measures. Investments in energy efficient technology, green building and sourcing of renewable energy can all lead to cost savings and reduce the company’s contribution to climate change.
Pollution Prevention
—N/A
Stemline Therapeutics on this issue. Companies are evaluated on pollution prevention by the levels of waste (including hazardous waste) they produce and release into the environment, and can be affected by whether they develop products that can reduce exposure to pollution.
Water Conservation
—N/A
Stemline Therapeutics among its peers in this category. A company’s score in this category depends on its measures to minimize water usage and impacts on stressed or drought-prone water resources.
Data & Privacy Protection
—N/A
Stemline Therapeutics among its peers and competitors for data privacy and protection. Companies today digitally manage vast amounts of personal information about their clients. A company’s score on this issue is based on the systems, products and procedures it has in place to minimize the risk for data and privacy breaches.
Consumer Health, Wellness & Safety
—N/A
Stemline Therapeutics compared to its peers and competitors Companies in this category manage its product and safety risks.
Employee Ownership, Satisfaction, Benefits & Pay
—N/A
Stemline Therapeutics among its peers for employee satisfaction and pay. A company’s score on this issue depends on its frequency and likelihood of labor disputes as well as its practices to keep and retain talent - such as compensation, family leave, employee health care and other benefits. Employers that are rated as good to work for consistently produce higher stock returns than their peers.
Workplace Health and Safety
—N/A
Stemline Therapeutics among its competitors on this issue. A company’s workplace health and safety is evaluated not only by the number of accidents and injuries in the workplace, but also by their safety policies, training procedures, and their investment in equipment that can reduce accidents.
Integrity of Corporate Governance
—N/A
Stemline Therapeutics among its competitors on corporate governance. This score is determined by the company’s accounting practices, executive pay, board organization and ownership structure.
Ethical Practices
—N/A
Stemline Therapeutics compared to its peers and competitors. A company’s rating on this issue is based on its history of controversies related to unethical corporate behavior, such as false claims about their products, price fixing, executive misconduct, insider trading or fraudulent practices.
Usage of Conflict Materials
—N/A
Stemline Therapeutics among its competitors in this category. Certain products use raw materials that are commonly sourced from militias or other organizations that promote or engage in conflict in their region. To perform well in this category companies must provide adequate assurances that any of these metals used in their production are in fact from conflict-free sources.
Forced Labor
—N/A
Stemline Therapeutics compared to its competitors on forced labor. A company’s score on this issue depends on its use of forced labor and on its work conditions for outsourced labor.
Diversity of Corporate Leadership
—N/A
Stemline Therapeutics based on its peers as well as companies in similar geographic regions. Companies are assessed on factors such as board diversity and senior management diversity. Companies performing well on this issue typically are more profitable than its peers, while companies with very poor scores typically have greater stock price volatility and lower returns on capital.

Stemline Therapeutics - Competitors and Related Companies

How Stemline Therapeutics stacks up to its peers in theBiotechnology industry or with competing business segments.